Core Viewpoint - The article discusses the ethical challenges within the medical profession, emphasizing that the commercialization of healthcare can lead to moral corruption among medical practitioners [14][29]. Group 1: Ethical Standards in Medicine - There is a societal expectation for doctors to maintain high ethical standards, as highlighted by historical references to medical ethics [3][4]. - The article argues that the medical profession is not immune to human flaws, and doctors can succumb to unethical practices, especially in a profit-driven environment [5][12]. Group 2: Case Study of Medical Malpractice - The case of Liu Xiangfeng, who engaged in severe malpractice, including unnecessary surgeries and organ trafficking, illustrates the potential for extreme unethical behavior in the medical field [11][12]. - The complicity of colleagues and the systemic issues within healthcare institutions contribute to the perpetuation of such unethical practices [10][12]. Group 3: Impact of Medical Commercialization - The commercialization of healthcare prioritizes financial gain over patient care, leading to a culture where unethical behavior can thrive [14][16]. - The article critiques the healthcare system's focus on profit, suggesting that it creates an environment conducive to corruption and malpractice [29][30]. Group 4: Need for Reform - The current healthcare system requires significant reform to address the ethical issues and ensure transparency in medical practices [27][30]. - The article advocates for a shift away from profit-driven metrics to a model that prioritizes patient welfare and ethical standards [28][30].

Group 1 - Trump's announcement to sign an executive order mandating a 30%-80% reduction in prescription drug prices has caused significant market volatility, particularly impacting Chinese biotech firm BeiGene, which saw a 10% drop in stock price on May 12 [1] - The biopharmaceutical sector experienced a rebound on May 13, with companies like Junshi Biosciences and BeiGene recovering some losses, indicating a complex market reaction to the announcement [1] - The announcement reflects deeper issues within the U.S. healthcare reform landscape, highlighting the political challenges and the lack of a clear implementation path for such policies [2] Group 2 - The U.S. pharmaceutical pricing system is characterized by a high investment cycle, with the top ten global pharmaceutical companies, eight of which are American, investing a total of $120.5 billion in R&D in 2023 [3] - The lobbying efforts of the Pharmaceutical Research and Manufacturers of America (PhRMA) are significant, with political contributions reaching $382.6 million in 2023, a 67% increase from 2016, indicating the industry's strong influence on policy [3] - The American Medical Association (AMA) controls pricing for medical services, which affects insurance premiums and creates a closed-loop profit chain among patients, insurers, and pharmaceutical companies [4] Group 3 - The U.S. healthcare reform challenges stem from the interplay of market beliefs, decentralized governance, and populist political demands, complicating any unilateral executive actions [5] - Legal challenges may arise from the Takings Clause of the U.S. Constitution, which protects corporate property rights, potentially hindering the implementation of price controls [5] - Cultural resistance to government intervention in healthcare is prevalent, with 63% of Americans believing that such actions would lower the quality of care, complicating the acceptance of unilateral pricing policies [5] Group 4 - The market reaction to Trump's pricing announcement reflects a pessimistic outlook on the uncertainty surrounding pharmaceutical companies, particularly in the context of global pricing dynamics [6] - The disparity in drug pricing between the U.S. and China highlights the critical role of the U.S. pricing system as a valuation anchor for global biopharmaceutical innovation [6] - Successful healthcare reforms in other countries, such as Germany and Japan, demonstrate that market access and affordability can coexist, suggesting that a balanced approach is necessary for U.S. healthcare reform [6] Group 5 - Chinese pharmaceutical companies are increasingly focusing on global expansion, leveraging technological advancements and compliance strategies to navigate market challenges [7] - Companies like BeiGene and Junshi Biosciences are establishing production bases in the U.S. to mitigate tariff risks and integrate into the global supply chain [7] - The recent policy turbulence underscores that Chinese innovative drug companies are evolving from followers to leaders in setting industry standards, as evidenced by significant licensing deals and advancements in cutting-edge therapies [7]